英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Novo Nordisk Loses Canadian Patent Protection For Blockbuster . . .
    Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- in Canada after failing to pay a $450 maintenance fee in 2019 The company had paid maintenance fees through 2018 but requested a refund for the 2017 fee, apparently seeking
  • Ozempic Patent Expires In Canada After Novo Nordisk Fails To . . .
    Danish pharma giant Novo Nordisk A S NVO faces potential financial losses related to its blockbuster weight-loss and diabetes drug, Ozempic, due to a regulatory issue According to Saynor, “Novo
  • A $250 mistake will cost Ozempic maker Novo Nordisk billions
    According to Lowe, Novo Nordisk did file a patent for semaglutide, the main component of their weight-loss and diabetes medicine, but failed to pay the annual maintenance fee on the patent
  • The story of how Novo Nordisk will lose billions because it . . .
    In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual $250 maintenance fee on time, but the company could maintain the patent by paying a total of $450
  • Novo Nordisks Canadian Mistake | Science - AAAS
    Saynor: Canada, we filed and are waiting for approval once the data exclusivity expires sometime in Q1 next year Interesting market Novo never filed a patent in Canada Never know why I’m sure someone’s lost their job, but never mind It’s the second-largest semaglutide market in the world Dunn: That’s pretty remarkable
  • Generic drug companies attack Novo Nordisk’s diabetes and . . .
    The Boards of Appeal of the European Patent Office have revoked two patents belonging to Novo Nordisk that are important for the administration of the diabetes and weight-loss drug semaglutide in tablet form
  • Semaglutide patent expiry opens door to GLP-1 generics in Canada
    What Novo Nordisk stands to lose in Canada and beyond The expiry of Novo Nordisk’s semaglutide patent in Canada might look small on paper, but the consequences could be substantial “There is no question that generic manufacturers are preparing for launch as soon as the Novo data exclusivity expires in January 2026





中文字典-英文字典  2005-2009